Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma
• The combination of anti-EGFR agents (CTX/NTZ) with concurrent chemoradiotherapy (CCRT) is comparable to induction chemotherapy (IC) plus CCRT treatment in survival outcomes for locoregionally advanced NPC patients. • Patients undergoing IC plus CCRT suffered from severe hematologic toxicity and di...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Lin, Mei [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
8 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole - 2012transfer abstract, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:80 ; year:2018 ; pages:1-8 ; extent:8 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.oraloncology.2018.03.002 |
|---|
| Katalog-ID: |
ELV042857333 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV042857333 | ||
| 003 | DE-627 | ||
| 005 | 20230624101330.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180726s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.oraloncology.2018.03.002 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000215A.pica |
| 035 | |a (DE-627)ELV042857333 | ||
| 035 | |a (ELSEVIER)S1368-8375(18)30086-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 650 |q VZ |
| 084 | |a 85.03 |2 bkl | ||
| 084 | |a 31.80 |2 bkl | ||
| 084 | |a 54.80 |2 bkl | ||
| 084 | |a 50.03 |2 bkl | ||
| 100 | 1 | |a Lin, Mei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma |
| 264 | 1 | |c 2018 | |
| 300 | |a 8 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • The combination of anti-EGFR agents (CTX/NTZ) with concurrent chemoradiotherapy (CCRT) is comparable to induction chemotherapy (IC) plus CCRT treatment in survival outcomes for locoregionally advanced NPC patients. • Patients undergoing IC plus CCRT suffered from severe hematologic toxicity and diarrhea compared with those treated with CTX/NTZ plus CCRT. • The addition of CTX/NTZ to CCRT is an effective and safe alternative treatment strategy for locoregionally advanced NPC patients. | ||
| 650 | 7 | |a Nasopharyngeal carcinoma |2 Elsevier | |
| 650 | 7 | |a IMRT |2 Elsevier | |
| 650 | 7 | |a Adverse events |2 Elsevier | |
| 650 | 7 | |a Concurrent chemoradiotherapy |2 Elsevier | |
| 650 | 7 | |a Survival outcome |2 Elsevier | |
| 650 | 7 | |a Cetuximab |2 Elsevier | |
| 650 | 7 | |a Nimotuzumab |2 Elsevier | |
| 700 | 1 | |a You, Rui |4 oth | |
| 700 | 1 | |a Liu, You-Ping |4 oth | |
| 700 | 1 | |a Zhang, Yi-Nuan |4 oth | |
| 700 | 1 | |a Zhang, Hao-Jiong |4 oth | |
| 700 | 1 | |a Zou, Xiong |4 oth | |
| 700 | 1 | |a Yang, Qi |4 oth | |
| 700 | 1 | |a Li, Chao-Feng |4 oth | |
| 700 | 1 | |a Hua, Yi-Jun |4 oth | |
| 700 | 1 | |a Yu, Tao |4 oth | |
| 700 | 1 | |a Cao, Jing-Yu |4 oth | |
| 700 | 1 | |a Li, Ji-Bin |4 oth | |
| 700 | 1 | |a Mo, Hao-Yuan |4 oth | |
| 700 | 1 | |a Guo, Ling |4 oth | |
| 700 | 1 | |a Lin, Ai-Hua |4 oth | |
| 700 | 1 | |a Sun, Ying |4 oth | |
| 700 | 1 | |a Qian, Chao-Nan |4 oth | |
| 700 | 1 | |a Ma, Jun |4 oth | |
| 700 | 1 | |a Mai, Hai-Qiang |4 oth | |
| 700 | 1 | |a Chen, Ming-Yuan |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |t Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |d 2012transfer abstract |g Amsterdam [u.a.] |w (DE-627)ELV011194073 |
| 773 | 1 | 8 | |g volume:80 |g year:2018 |g pages:1-8 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.oraloncology.2018.03.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OPC-MAT | ||
| 936 | b | k | |a 85.03 |j Methoden und Techniken der Betriebswirtschaft |q VZ |
| 936 | b | k | |a 31.80 |j Angewandte Mathematik |q VZ |
| 936 | b | k | |a 54.80 |j Angewandte Informatik |q VZ |
| 936 | b | k | |a 50.03 |j Methoden und Techniken der Ingenieurwissenschaften |q VZ |
| 951 | |a AR | ||
| 952 | |d 80 |j 2018 |h 1-8 |g 8 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
m l ml |
|---|---|
| matchkey_str |
linmeiyouruiliuyoupingzhangyinuanzhangha:2018----:eeiilfetoatefaetctxmbriouuaicmiainihocrethmrdohrp |
| hierarchy_sort_str |
2018 |
| bklnumber |
85.03 31.80 54.80 50.03 |
| publishDate |
2018 |
| allfields |
10.1016/j.oraloncology.2018.03.002 doi GBV00000000000215A.pica (DE-627)ELV042857333 (ELSEVIER)S1368-8375(18)30086-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Lin, Mei verfasserin aut Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma 2018 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • The combination of anti-EGFR agents (CTX/NTZ) with concurrent chemoradiotherapy (CCRT) is comparable to induction chemotherapy (IC) plus CCRT treatment in survival outcomes for locoregionally advanced NPC patients. • Patients undergoing IC plus CCRT suffered from severe hematologic toxicity and diarrhea compared with those treated with CTX/NTZ plus CCRT. • The addition of CTX/NTZ to CCRT is an effective and safe alternative treatment strategy for locoregionally advanced NPC patients. Nasopharyngeal carcinoma Elsevier IMRT Elsevier Adverse events Elsevier Concurrent chemoradiotherapy Elsevier Survival outcome Elsevier Cetuximab Elsevier Nimotuzumab Elsevier You, Rui oth Liu, You-Ping oth Zhang, Yi-Nuan oth Zhang, Hao-Jiong oth Zou, Xiong oth Yang, Qi oth Li, Chao-Feng oth Hua, Yi-Jun oth Yu, Tao oth Cao, Jing-Yu oth Li, Ji-Bin oth Mo, Hao-Yuan oth Guo, Ling oth Lin, Ai-Hua oth Sun, Ying oth Qian, Chao-Nan oth Ma, Jun oth Mai, Hai-Qiang oth Chen, Ming-Yuan oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:80 year:2018 pages:1-8 extent:8 https://doi.org/10.1016/j.oraloncology.2018.03.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 80 2018 1-8 8 045F 610 |
| spelling |
10.1016/j.oraloncology.2018.03.002 doi GBV00000000000215A.pica (DE-627)ELV042857333 (ELSEVIER)S1368-8375(18)30086-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Lin, Mei verfasserin aut Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma 2018 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • The combination of anti-EGFR agents (CTX/NTZ) with concurrent chemoradiotherapy (CCRT) is comparable to induction chemotherapy (IC) plus CCRT treatment in survival outcomes for locoregionally advanced NPC patients. • Patients undergoing IC plus CCRT suffered from severe hematologic toxicity and diarrhea compared with those treated with CTX/NTZ plus CCRT. • The addition of CTX/NTZ to CCRT is an effective and safe alternative treatment strategy for locoregionally advanced NPC patients. Nasopharyngeal carcinoma Elsevier IMRT Elsevier Adverse events Elsevier Concurrent chemoradiotherapy Elsevier Survival outcome Elsevier Cetuximab Elsevier Nimotuzumab Elsevier You, Rui oth Liu, You-Ping oth Zhang, Yi-Nuan oth Zhang, Hao-Jiong oth Zou, Xiong oth Yang, Qi oth Li, Chao-Feng oth Hua, Yi-Jun oth Yu, Tao oth Cao, Jing-Yu oth Li, Ji-Bin oth Mo, Hao-Yuan oth Guo, Ling oth Lin, Ai-Hua oth Sun, Ying oth Qian, Chao-Nan oth Ma, Jun oth Mai, Hai-Qiang oth Chen, Ming-Yuan oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:80 year:2018 pages:1-8 extent:8 https://doi.org/10.1016/j.oraloncology.2018.03.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 80 2018 1-8 8 045F 610 |
| allfields_unstemmed |
10.1016/j.oraloncology.2018.03.002 doi GBV00000000000215A.pica (DE-627)ELV042857333 (ELSEVIER)S1368-8375(18)30086-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Lin, Mei verfasserin aut Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma 2018 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • The combination of anti-EGFR agents (CTX/NTZ) with concurrent chemoradiotherapy (CCRT) is comparable to induction chemotherapy (IC) plus CCRT treatment in survival outcomes for locoregionally advanced NPC patients. • Patients undergoing IC plus CCRT suffered from severe hematologic toxicity and diarrhea compared with those treated with CTX/NTZ plus CCRT. • The addition of CTX/NTZ to CCRT is an effective and safe alternative treatment strategy for locoregionally advanced NPC patients. Nasopharyngeal carcinoma Elsevier IMRT Elsevier Adverse events Elsevier Concurrent chemoradiotherapy Elsevier Survival outcome Elsevier Cetuximab Elsevier Nimotuzumab Elsevier You, Rui oth Liu, You-Ping oth Zhang, Yi-Nuan oth Zhang, Hao-Jiong oth Zou, Xiong oth Yang, Qi oth Li, Chao-Feng oth Hua, Yi-Jun oth Yu, Tao oth Cao, Jing-Yu oth Li, Ji-Bin oth Mo, Hao-Yuan oth Guo, Ling oth Lin, Ai-Hua oth Sun, Ying oth Qian, Chao-Nan oth Ma, Jun oth Mai, Hai-Qiang oth Chen, Ming-Yuan oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:80 year:2018 pages:1-8 extent:8 https://doi.org/10.1016/j.oraloncology.2018.03.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 80 2018 1-8 8 045F 610 |
| allfieldsGer |
10.1016/j.oraloncology.2018.03.002 doi GBV00000000000215A.pica (DE-627)ELV042857333 (ELSEVIER)S1368-8375(18)30086-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Lin, Mei verfasserin aut Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma 2018 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • The combination of anti-EGFR agents (CTX/NTZ) with concurrent chemoradiotherapy (CCRT) is comparable to induction chemotherapy (IC) plus CCRT treatment in survival outcomes for locoregionally advanced NPC patients. • Patients undergoing IC plus CCRT suffered from severe hematologic toxicity and diarrhea compared with those treated with CTX/NTZ plus CCRT. • The addition of CTX/NTZ to CCRT is an effective and safe alternative treatment strategy for locoregionally advanced NPC patients. Nasopharyngeal carcinoma Elsevier IMRT Elsevier Adverse events Elsevier Concurrent chemoradiotherapy Elsevier Survival outcome Elsevier Cetuximab Elsevier Nimotuzumab Elsevier You, Rui oth Liu, You-Ping oth Zhang, Yi-Nuan oth Zhang, Hao-Jiong oth Zou, Xiong oth Yang, Qi oth Li, Chao-Feng oth Hua, Yi-Jun oth Yu, Tao oth Cao, Jing-Yu oth Li, Ji-Bin oth Mo, Hao-Yuan oth Guo, Ling oth Lin, Ai-Hua oth Sun, Ying oth Qian, Chao-Nan oth Ma, Jun oth Mai, Hai-Qiang oth Chen, Ming-Yuan oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:80 year:2018 pages:1-8 extent:8 https://doi.org/10.1016/j.oraloncology.2018.03.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 80 2018 1-8 8 045F 610 |
| allfieldsSound |
10.1016/j.oraloncology.2018.03.002 doi GBV00000000000215A.pica (DE-627)ELV042857333 (ELSEVIER)S1368-8375(18)30086-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Lin, Mei verfasserin aut Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma 2018 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • The combination of anti-EGFR agents (CTX/NTZ) with concurrent chemoradiotherapy (CCRT) is comparable to induction chemotherapy (IC) plus CCRT treatment in survival outcomes for locoregionally advanced NPC patients. • Patients undergoing IC plus CCRT suffered from severe hematologic toxicity and diarrhea compared with those treated with CTX/NTZ plus CCRT. • The addition of CTX/NTZ to CCRT is an effective and safe alternative treatment strategy for locoregionally advanced NPC patients. Nasopharyngeal carcinoma Elsevier IMRT Elsevier Adverse events Elsevier Concurrent chemoradiotherapy Elsevier Survival outcome Elsevier Cetuximab Elsevier Nimotuzumab Elsevier You, Rui oth Liu, You-Ping oth Zhang, Yi-Nuan oth Zhang, Hao-Jiong oth Zou, Xiong oth Yang, Qi oth Li, Chao-Feng oth Hua, Yi-Jun oth Yu, Tao oth Cao, Jing-Yu oth Li, Ji-Bin oth Mo, Hao-Yuan oth Guo, Ling oth Lin, Ai-Hua oth Sun, Ying oth Qian, Chao-Nan oth Ma, Jun oth Mai, Hai-Qiang oth Chen, Ming-Yuan oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:80 year:2018 pages:1-8 extent:8 https://doi.org/10.1016/j.oraloncology.2018.03.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 80 2018 1-8 8 045F 610 |
| language |
English |
| source |
Enthalten in Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole Amsterdam [u.a.] volume:80 year:2018 pages:1-8 extent:8 |
| sourceStr |
Enthalten in Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole Amsterdam [u.a.] volume:80 year:2018 pages:1-8 extent:8 |
| format_phy_str_mv |
Article |
| bklname |
Methoden und Techniken der Betriebswirtschaft Angewandte Mathematik Angewandte Informatik Methoden und Techniken der Ingenieurwissenschaften |
| institution |
findex.gbv.de |
| topic_facet |
Nasopharyngeal carcinoma IMRT Adverse events Concurrent chemoradiotherapy Survival outcome Cetuximab Nimotuzumab |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| authorswithroles_txt_mv |
Lin, Mei @@aut@@ You, Rui @@oth@@ Liu, You-Ping @@oth@@ Zhang, Yi-Nuan @@oth@@ Zhang, Hao-Jiong @@oth@@ Zou, Xiong @@oth@@ Yang, Qi @@oth@@ Li, Chao-Feng @@oth@@ Hua, Yi-Jun @@oth@@ Yu, Tao @@oth@@ Cao, Jing-Yu @@oth@@ Li, Ji-Bin @@oth@@ Mo, Hao-Yuan @@oth@@ Guo, Ling @@oth@@ Lin, Ai-Hua @@oth@@ Sun, Ying @@oth@@ Qian, Chao-Nan @@oth@@ Ma, Jun @@oth@@ Mai, Hai-Qiang @@oth@@ Chen, Ming-Yuan @@oth@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
ELV011194073 |
| dewey-sort |
3610 |
| id |
ELV042857333 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV042857333</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624101330.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.oraloncology.2018.03.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000215A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV042857333</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1368-8375(18)30086-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">650</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">85.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">50.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lin, Mei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• The combination of anti-EGFR agents (CTX/NTZ) with concurrent chemoradiotherapy (CCRT) is comparable to induction chemotherapy (IC) plus CCRT treatment in survival outcomes for locoregionally advanced NPC patients. • Patients undergoing IC plus CCRT suffered from severe hematologic toxicity and diarrhea compared with those treated with CTX/NTZ plus CCRT. • The addition of CTX/NTZ to CCRT is an effective and safe alternative treatment strategy for locoregionally advanced NPC patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Nasopharyngeal carcinoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IMRT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Adverse events</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Concurrent chemoradiotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Survival outcome</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cetuximab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Nimotuzumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">You, Rui</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, You-Ping</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhang, Yi-Nuan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhang, Hao-Jiong</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zou, Xiong</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Qi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Chao-Feng</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hua, Yi-Jun</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yu, Tao</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cao, Jing-Yu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Ji-Bin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mo, Hao-Yuan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guo, Ling</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lin, Ai-Hua</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sun, Ying</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Qian, Chao-Nan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ma, Jun</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mai, Hai-Qiang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Ming-Yuan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole</subfield><subfield code="d">2012transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011194073</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:80</subfield><subfield code="g">year:2018</subfield><subfield code="g">pages:1-8</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.oraloncology.2018.03.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">85.03</subfield><subfield code="j">Methoden und Techniken der Betriebswirtschaft</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.80</subfield><subfield code="j">Angewandte Mathematik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.80</subfield><subfield code="j">Angewandte Informatik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">50.03</subfield><subfield code="j">Methoden und Techniken der Ingenieurwissenschaften</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">80</subfield><subfield code="j">2018</subfield><subfield code="h">1-8</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Lin, Mei |
| spellingShingle |
Lin, Mei ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier Nasopharyngeal carcinoma Elsevier IMRT Elsevier Adverse events Elsevier Concurrent chemoradiotherapy Elsevier Survival outcome Elsevier Cetuximab Elsevier Nimotuzumab Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma |
| authorStr |
Lin, Mei |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV011194073 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 650 - Management & auxiliary services |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma Nasopharyngeal carcinoma Elsevier IMRT Elsevier Adverse events Elsevier Concurrent chemoradiotherapy Elsevier Survival outcome Elsevier Cetuximab Elsevier Nimotuzumab Elsevier |
| topic |
ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier Nasopharyngeal carcinoma Elsevier IMRT Elsevier Adverse events Elsevier Concurrent chemoradiotherapy Elsevier Survival outcome Elsevier Cetuximab Elsevier Nimotuzumab |
| topic_unstemmed |
ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier Nasopharyngeal carcinoma Elsevier IMRT Elsevier Adverse events Elsevier Concurrent chemoradiotherapy Elsevier Survival outcome Elsevier Cetuximab Elsevier Nimotuzumab |
| topic_browse |
ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier Nasopharyngeal carcinoma Elsevier IMRT Elsevier Adverse events Elsevier Concurrent chemoradiotherapy Elsevier Survival outcome Elsevier Cetuximab Elsevier Nimotuzumab |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
r y ry y p l ypl y n z ynz h j z hjz x z xz q y qy c f l cfl y j h yjh t y ty j y c jyc j b l jbl h y m hym l g lg a h l ahl y s ys c n q cnq j m jm h q m hqm m y c myc |
| hierarchy_parent_title |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| hierarchy_parent_id |
ELV011194073 |
| dewey-tens |
610 - Medicine & health 650 - Management & public relations |
| hierarchy_top_title |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV011194073 |
| title |
Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma |
| ctrlnum |
(DE-627)ELV042857333 (ELSEVIER)S1368-8375(18)30086-1 |
| title_full |
Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma |
| author_sort |
Lin, Mei |
| journal |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| journalStr |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
zzz |
| container_start_page |
1 |
| author_browse |
Lin, Mei |
| container_volume |
80 |
| physical |
8 |
| class |
610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Lin, Mei |
| doi_str_mv |
10.1016/j.oraloncology.2018.03.002 |
| dewey-full |
610 650 |
| title_sort |
beneficial effects of anti-egfr agents, cetuximab or nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma |
| title_auth |
Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma |
| abstract |
• The combination of anti-EGFR agents (CTX/NTZ) with concurrent chemoradiotherapy (CCRT) is comparable to induction chemotherapy (IC) plus CCRT treatment in survival outcomes for locoregionally advanced NPC patients. • Patients undergoing IC plus CCRT suffered from severe hematologic toxicity and diarrhea compared with those treated with CTX/NTZ plus CCRT. • The addition of CTX/NTZ to CCRT is an effective and safe alternative treatment strategy for locoregionally advanced NPC patients. |
| abstractGer |
• The combination of anti-EGFR agents (CTX/NTZ) with concurrent chemoradiotherapy (CCRT) is comparable to induction chemotherapy (IC) plus CCRT treatment in survival outcomes for locoregionally advanced NPC patients. • Patients undergoing IC plus CCRT suffered from severe hematologic toxicity and diarrhea compared with those treated with CTX/NTZ plus CCRT. • The addition of CTX/NTZ to CCRT is an effective and safe alternative treatment strategy for locoregionally advanced NPC patients. |
| abstract_unstemmed |
• The combination of anti-EGFR agents (CTX/NTZ) with concurrent chemoradiotherapy (CCRT) is comparable to induction chemotherapy (IC) plus CCRT treatment in survival outcomes for locoregionally advanced NPC patients. • Patients undergoing IC plus CCRT suffered from severe hematologic toxicity and diarrhea compared with those treated with CTX/NTZ plus CCRT. • The addition of CTX/NTZ to CCRT is an effective and safe alternative treatment strategy for locoregionally advanced NPC patients. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT |
| title_short |
Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma |
| url |
https://doi.org/10.1016/j.oraloncology.2018.03.002 |
| remote_bool |
true |
| author2 |
You, Rui Liu, You-Ping Zhang, Yi-Nuan Zhang, Hao-Jiong Zou, Xiong Yang, Qi Li, Chao-Feng Hua, Yi-Jun Yu, Tao Cao, Jing-Yu Li, Ji-Bin Mo, Hao-Yuan Guo, Ling Lin, Ai-Hua Sun, Ying Qian, Chao-Nan Ma, Jun Mai, Hai-Qiang Chen, Ming-Yuan |
| author2Str |
You, Rui Liu, You-Ping Zhang, Yi-Nuan Zhang, Hao-Jiong Zou, Xiong Yang, Qi Li, Chao-Feng Hua, Yi-Jun Yu, Tao Cao, Jing-Yu Li, Ji-Bin Mo, Hao-Yuan Guo, Ling Lin, Ai-Hua Sun, Ying Qian, Chao-Nan Ma, Jun Mai, Hai-Qiang Chen, Ming-Yuan |
| ppnlink |
ELV011194073 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.oraloncology.2018.03.002 |
| up_date |
2024-07-06T17:17:38.420Z |
| _version_ |
1803850883710058496 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV042857333</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624101330.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.oraloncology.2018.03.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000215A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV042857333</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1368-8375(18)30086-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">650</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">85.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">50.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lin, Mei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• The combination of anti-EGFR agents (CTX/NTZ) with concurrent chemoradiotherapy (CCRT) is comparable to induction chemotherapy (IC) plus CCRT treatment in survival outcomes for locoregionally advanced NPC patients. • Patients undergoing IC plus CCRT suffered from severe hematologic toxicity and diarrhea compared with those treated with CTX/NTZ plus CCRT. • The addition of CTX/NTZ to CCRT is an effective and safe alternative treatment strategy for locoregionally advanced NPC patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Nasopharyngeal carcinoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IMRT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Adverse events</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Concurrent chemoradiotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Survival outcome</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cetuximab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Nimotuzumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">You, Rui</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, You-Ping</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhang, Yi-Nuan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhang, Hao-Jiong</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zou, Xiong</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Qi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Chao-Feng</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hua, Yi-Jun</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yu, Tao</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cao, Jing-Yu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Ji-Bin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mo, Hao-Yuan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guo, Ling</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lin, Ai-Hua</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sun, Ying</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Qian, Chao-Nan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ma, Jun</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mai, Hai-Qiang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Ming-Yuan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole</subfield><subfield code="d">2012transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011194073</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:80</subfield><subfield code="g">year:2018</subfield><subfield code="g">pages:1-8</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.oraloncology.2018.03.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">85.03</subfield><subfield code="j">Methoden und Techniken der Betriebswirtschaft</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.80</subfield><subfield code="j">Angewandte Mathematik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.80</subfield><subfield code="j">Angewandte Informatik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">50.03</subfield><subfield code="j">Methoden und Techniken der Ingenieurwissenschaften</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">80</subfield><subfield code="j">2018</subfield><subfield code="h">1-8</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.399987 |